However, whether detecting the aberrant methylation of CCND2 in the blood samples of patients can be applied as a noninvasive analytical method for early diagnosis, prognosis, or precision medicine in breast cancer and lung cancer patients is worth further massive screening and investigation. The gene discussed is CCND2; the disease is breast cancer.